Skip to main content
SpringerLink
Log in

Recombinant Human Erythropoietin — could it be used in a Better Way?

  • Chapter
Alternative Approaches to Human Blood Resources in Clinical Practice

Part of the book series: Developments in Hematology and Immunology ((DIHI,volume 33))

  • 79 Accesses

Abstract

Recombinant human erythropoietin (EPO) therapy has now been approved for use in patients undergoing autologous blood donation (ABD) in Japan, the European Union, and Canada since 1993, 1994, and 1996 respectively, and for perisurgical adjuvant therapy without ABD in Canada and the US since 1966. This paper is intended to provide a framework for clinicians who will have the options of administering EPO therapy to patients undergoing surgery, and to provide a better understanding of its proper use in this setting [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl Med 1997; 336:933–938.

    Article  CAS  Google Scholar 

  2. Goodnough LT, Brittenham G. Limitations of the erythropoietic response to serial phlebotomy: implications of autologous blood donor programs. J Lab Clin Med 1990; 115:28–35.

    PubMed  CAS  Google Scholar 

  3. Kickler TS, Spivak JL. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA 1988;260:65–67.

    Article  PubMed  CAS  Google Scholar 

  4. Goodnough LT, Rudnick S, Price TH, et al. Increased collection of autologous blood preoperatively with recombinant human erythropoietin therapy. N Engl J Med 1989; 321:1163–1167.

    Article  PubMed  CAS  Google Scholar 

  5. Goodnough LT, Price TH, Rudnick S. Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 1992;32:441–445.

    Article  PubMed  CAS  Google Scholar 

  6. Goodnough LT, Price TH and the EPO Study Group. A phase III trial of recombinant human erythropoietin therapy in non-anaemic orthopaedic patients subjected to aggressive autologous blood phlebotomy: dose, response, toxicity, and efficacy. Transfusion 1994;34:66–71.

    Article  PubMed  CAS  Google Scholar 

  7. Beris P, Mermillod B, Levy G, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. Vox Sang 1993;65:212–218.

    Article  PubMed  CAS  Google Scholar 

  8. Biesma DH, Marx JJ, Kraaijenhagen RJ, Franke W, Messinger D, van der Wiel A. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 1994;344:367–370.

    Article  PubMed  CAS  Google Scholar 

  9. Goodnough LT, Monk TG, Brecher MF. Autologous blood procurement: lessons to be learned in the last 10 years. Vox Sang 1996;71:133–141.

    Article  PubMed  CAS  Google Scholar 

  10. Mercuriali F, Zanella A, Barosi G, et al. Use erythropoietin to increase the volume of autologous blood donated by orthopaedic patients. Transfusion 1993;33:55–60.

    Article  PubMed  CAS  Google Scholar 

  11. Price TH, Goodnough LT, Vogler W, et al. The effect of recombinant erythropoietin administration on the efficacy of autologous blood donation in patients with low haematocrits. Transfusion 1996;36:29–36.

    Article  PubMed  CAS  Google Scholar 

  12. Canadian orthopedic perioperative erythropoietin study group. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993;341:1227–1232.

    Google Scholar 

  13. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on preoperative transfusion requirements in patients undergoing major orthopaedic surgery. J Bone Surg 1996;78A:62–72.

    Google Scholar 

  14. De Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC. Baseline hemoglobin as a predictor of risk of transfusion and response to epoietin alpha in orthopedic surgery patients. Amer J Orth 1996;25:533–542.

    Google Scholar 

  15. Goodnough LT, Price TH, Parvin CA, et al. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Brit J Haem 1994;87:695–699.

    Article  CAS  Google Scholar 

  16. Toy PTCY, Kaplan EB, McVay PA, et al. Blood loss and replacement in total hip arthroplasty: a multicenter study. Transfusion 1992;32:63–67.

    Article  PubMed  CAS  Google Scholar 

  17. Goodnough LT, Vizmeg K, Marcus RE. Blood lost and transfused in patients undergoing elective orthopaedic operation. Implications for blood conservation programs. SurgGynec Obstet 1993; 176:235–238.

    PubMed  CAS  Google Scholar 

  18. Sisk JE, Gianfrancesco FD, Costner JM. Recombinant erythropoietin and medicare payment. JAMA 199;266:247–252.

    Google Scholar 

  19. Doolittle RF. Biotechnology’ the enormous cost of success. N Engl J Med 1991; 324:1360–1362.

    Article  PubMed  CAS  Google Scholar 

  20. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76:1718–1722.

    PubMed  CAS  Google Scholar 

  21. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of erythropoietin alpha in patients undergoing major orhtopedic surgery. Amer J Ortop 1996;25:544–552.

    CAS  Google Scholar 

  22. Messmer K, Kreimeier M, Intagliett A. Present state of intentional hemodilution. Eur Surg Res 1986; 18:254–263.

    Article  PubMed  CAS  Google Scholar 

  23. Monk TG, Goodnough LT, Birkmeyer JD, Brecher ME, Catalona WJ. Acute normovolemic hemodulition is a cost-effective alternative to preoperative autologous donation in patients undergoing radical retropubic prostatectomy. Transfusion 1995;35: 559–565.

    Article  PubMed  CAS  Google Scholar 

  24. Monk TH, Goodnough LT, Pulley DD, Brecher ME, et al. Acute normovolemic hemodilution can replace preoperative autologous blood donation as a standard of care for autologous blood procurement in patients undergoing radical prostatectomy procedures. Anesth Analg 1997;85:953–958.

    PubMed  CAS  Google Scholar 

  25. Monk TG, Goodnough LT, Andriole GL, Colberg JW, Lemon DJ, Martin K. Preoperative recombinant human erythropoietin therapy enhances the efficacy of acute normovolemic hemodilution. Anesth Analg 1995;80:S320.

    Google Scholar 

  26. Andriole GL, Smith DS, Rao G, Goodnough LT, Catalona WJ. Early complications of contemporary anatomic radical retropubic prostatectomy. J Urology 1994; 152: 158–160.

    Google Scholar 

  27. Goodnough LT, Bodner MS, Martin JW. Blood transfusion and blood conservation: cost and utilization issues. Amer J Med Qual 1994;9:172–183.

    Article  CAS  Google Scholar 

  28. Sowade O, Warnke H, Scigalla P, et al. Avoidance of allogeneic blood transfusions by treatment with epoietin alpha (recombinant human erythropoietin) in patients undergoing open heart surgery. Blood 1997:89:411–418.

    PubMed  CAS  Google Scholar 

  29. Welch GH, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116:393–402.

    PubMed  CAS  Google Scholar 

  30. Goodnough LT. Blood transfusion and blood conservation practices. Flip sides of the same coin? Ann Thor Surg 1993;56:1437–1441.

    Article  Google Scholar 

  31. Sans T, Bofill C, Joven J, Cliville X, et al. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin for autologous blood donation before orthopedic surgery. Transfusion 1996;36:822–826.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. L. T. Goodnough
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Red Cross Blood Bank Noord Nederland, The Netherlands

    C. Th. Smit Sibinga  & P. C. Das  & 

  2. C.L. Mclntosh & Ass., Rockville, MD, USA

    J. C. Fratantoni

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Goodnough, L.T. (1998). Recombinant Human Erythropoietin — could it be used in a Better Way?. In: Sibinga, C.T.S., Das, P.C., Fratantoni, J.C. (eds) Alternative Approaches to Human Blood Resources in Clinical Practice. Developments in Hematology and Immunology, vol 33. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5619-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5619-0_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7571-5

  • Online ISBN: 978-1-4615-5619-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation